GoodRx Holdings Research and Development Expenses 2019-2024 | GDRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GoodRx Holdings research and development expenses from 2019 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

GoodRx Holdings Research and Development Expenses 2019-2024 | GDRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GoodRx Holdings research and development expenses from 2019 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$125.1B
Cencora (COR)	$45B
ICON (ICLR)	$25B
DiDi Global (DIDIY)	$19B
Avantor (AVTR)	$18.4B
Natera (NTRA)	$15.7B
Revvity (RVTY)	$15.4B
Viatris (VTRS)	$14.2B
CochLear (CHEOY)	$12.8B
Solventum (SOLV)	$12.5B
Medpace Holdings (MEDP)	$11.2B
Charles River Laboratories (CRL)	$10.6B
Sonic Healthcare (SKHHY)	$8.8B
Doximity (DOCS)	$7.4B
Bausch + Lomb (BLCO)	$7B
HealthEquity (HQY)	$6.8B
PACS (PACS)	$6.2B
Organon (OGN)	$5.1B
Life Times (LTH)	$4.9B
Sotera Health (SHC)	$4.7B
Surgery Partners (SGRY)	$4.1B
Concentras Parent (CON)	$3B
BrightSpring Health Services (BTSG)	$2.5B
Ardent Health Partners (ARDT)	$2.4B
Progyny (PGNY)	$2.2B
Alignment Healthcare (ALHC)	$2.2B
Premier (PINC)	$2.1B
Ryman Healthcare (RYHTY)	$1.9B
AMN Healthcare Services Inc (AMN)	$1.8B
Agilon Health (AGL)	$1.6B